Single dose administration of CD32B x CD79B bispecific DART® molecule delivers an immunomodulatory effect that counters B-cell function
ROCKVILLE, MD, USA I June 17, 2017 I MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of updated data from its Phase 1 study of MGD010 at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Madrid, Spain.
In a poster titled “Immunomodulatory Effects of MGD010, a DART® Molecule Targeting Human B-cell CD32B and CD79B,” the Company highlighted the immunomodulatory impact of MGD010 on the response to hepatitis A vaccination (HAV), a model antigen challenge, in normal healthy subjects. These data demonstrate that by pharmacologically exploiting the activity of the checkpoint molecule CD32B in combination with the B-cell receptor (BCR) CD79B component, a single dose administration of MGD010 at either 3 or 10 mg/kg delivers an immunomodulatory effect that counters B-cell function.
In this portion of the Phase 1 study, 23 evaluable healthy subjects received 3 or 10 mg/kg MGD010 or placebo, followed by HAV immunization. There were no CTCAE grade 3 or higher adverse events related to MGD010. Consistent with prior observations, ex vivo flow cytometric analysis confirmed dose-dependent MGD010 binding to peripheral B cells without B-cell depletion, accompanied by decreased surface BCR and CD40 expression as well as a decrease in total serum IgM levels. Compared to the placebo group, reduced HAV seroconversion rates were observed in subjects treated with MGD010, with significantly lower HA-specific IgG levels.
“The updated data regarding HAV seroconversion further confirm that MGD010 can exert immunomodulatory activity in vivo consistent with its intended mechanism of action. Combined with its good safety profile, these results provide compelling rationale for further development of this therapeutic modality for autoimmune disorders,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
The poster is available for download from the Events & Presentations page on MacroGenics’ website at http://ir.macrogenics.com/events.cfm.
About MGD010
MGD010 is a humanized DART molecule that simultaneously targets CD32B and CD79B. This product candidate is the first clinical autoimmune-focused DART program. In normal conditions, B cells utilize the checkpoint receptor, CD32B, as one of the key negative regulators to ensure that tolerance to self is maintained and autoimmune disorders do not occur. MGD010 exploits this mechanism and triggers this immune checkpoint loop for the inhibition of B-cell function, an approach that may be useful for the treatment of patients with autoimmune disorders.
MacroGenics reported initial data from a Phase 1 study of MGD010 at EULAR 2016. The initial portion of this study was a first-in-human, double-blind, placebo-controlled study in which a single dose of MGD010 was intravenously (IV) administered to 49 healthy subjects. Data from the study showed that the molecule was well tolerated at all dose levels and no serious adverse effects were reported. None of the subjects participating in the study had premature discontinuations or infusion reactions, systemic hypersensitivity reactions or injection site reactions.
The data from this study demonstrated that MGD010 was well tolerated as a single dose up to 10 mg/kg, with no evidence of peripheral B-cell activation or depletion. Moreover, MGD010 exhibited: (1) linear pharmacokinetics with properties similar to those of an antibody molecule, (2) dose-dependent B-cell occupancy (with saturation >1 mg/kg), (3) down-modulation of BCR expression among circulating memory and naïve B cells, (4) downregulation of BCR-induced signaling and diminished propensity for ex-vivo BCR-induced B-cell activation, (5) a decrease in expression of the costimulatory CD40 molecule, and (6) a decrease in circulating immunoglobulin M levels.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
SOURCE: MacroGenics
Post Views: 270
Single dose administration of CD32B x CD79B bispecific DART® molecule delivers an immunomodulatory effect that counters B-cell function
ROCKVILLE, MD, USA I June 17, 2017 I MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the presentation of updated data from its Phase 1 study of MGD010 at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Madrid, Spain.
In a poster titled “Immunomodulatory Effects of MGD010, a DART® Molecule Targeting Human B-cell CD32B and CD79B,” the Company highlighted the immunomodulatory impact of MGD010 on the response to hepatitis A vaccination (HAV), a model antigen challenge, in normal healthy subjects. These data demonstrate that by pharmacologically exploiting the activity of the checkpoint molecule CD32B in combination with the B-cell receptor (BCR) CD79B component, a single dose administration of MGD010 at either 3 or 10 mg/kg delivers an immunomodulatory effect that counters B-cell function.
In this portion of the Phase 1 study, 23 evaluable healthy subjects received 3 or 10 mg/kg MGD010 or placebo, followed by HAV immunization. There were no CTCAE grade 3 or higher adverse events related to MGD010. Consistent with prior observations, ex vivo flow cytometric analysis confirmed dose-dependent MGD010 binding to peripheral B cells without B-cell depletion, accompanied by decreased surface BCR and CD40 expression as well as a decrease in total serum IgM levels. Compared to the placebo group, reduced HAV seroconversion rates were observed in subjects treated with MGD010, with significantly lower HA-specific IgG levels.
“The updated data regarding HAV seroconversion further confirm that MGD010 can exert immunomodulatory activity in vivo consistent with its intended mechanism of action. Combined with its good safety profile, these results provide compelling rationale for further development of this therapeutic modality for autoimmune disorders,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
The poster is available for download from the Events & Presentations page on MacroGenics’ website at http://ir.macrogenics.com/events.cfm.
About MGD010
MGD010 is a humanized DART molecule that simultaneously targets CD32B and CD79B. This product candidate is the first clinical autoimmune-focused DART program. In normal conditions, B cells utilize the checkpoint receptor, CD32B, as one of the key negative regulators to ensure that tolerance to self is maintained and autoimmune disorders do not occur. MGD010 exploits this mechanism and triggers this immune checkpoint loop for the inhibition of B-cell function, an approach that may be useful for the treatment of patients with autoimmune disorders.
MacroGenics reported initial data from a Phase 1 study of MGD010 at EULAR 2016. The initial portion of this study was a first-in-human, double-blind, placebo-controlled study in which a single dose of MGD010 was intravenously (IV) administered to 49 healthy subjects. Data from the study showed that the molecule was well tolerated at all dose levels and no serious adverse effects were reported. None of the subjects participating in the study had premature discontinuations or infusion reactions, systemic hypersensitivity reactions or injection site reactions.
The data from this study demonstrated that MGD010 was well tolerated as a single dose up to 10 mg/kg, with no evidence of peripheral B-cell activation or depletion. Moreover, MGD010 exhibited: (1) linear pharmacokinetics with properties similar to those of an antibody molecule, (2) dose-dependent B-cell occupancy (with saturation >1 mg/kg), (3) down-modulation of BCR expression among circulating memory and naïve B cells, (4) downregulation of BCR-induced signaling and diminished propensity for ex-vivo BCR-induced B-cell activation, (5) a decrease in expression of the costimulatory CD40 molecule, and (6) a decrease in circulating immunoglobulin M levels.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.
SOURCE: MacroGenics
Post Views: 270
